Novo Nordisk A/S (NVO) Stock: Drops as Semaglutide Helps 40% of Children Exit Obesity Classification

TLDR

Table of Contents

Semaglutide helped 40.4% of children move below the obesity threshold in STEP Young.
NVO stock fell 1.92% as Novo Nordisk reported positive STEP Young trial results.
STEP Young met its main goal with stronger BMI reductions than placebo at week 68.
No new safety concerns emerged for growth or puberty in the STEP Young trial.
Novo Nordisk will present STEP Young results at ObesityWeek 2026 in November.

Novo Nordisk (NVO) shares closed at $46.60, down 1.92%, while after-hours trading slipped to $46.55. The move followed new results from the company’s STEP Young phase 3 obesity trial. Semaglutide helped about 40% of treated children move below the study’s obesity classification threshold.

Novo Nordisk A/S, NVO

STEP Young Trial Meets Primary Endpoint

Novo Nordisk tested once-weekly semaglutide in children aged six to under 12 years with obesity. The trial paired treatment with a reduced-calorie diet and increased physical activity. Researchers compared semaglutide against placebo for 68 weeks and measured changes in body mass index.

The study met its primary endpoint after semaglutide produced a greater BMI reduction than placebo. At week 68, 40.4% of treated children no longer met the study’s obesity classification. Meanwhile, no children receiving placebo moved below the obesity threshold during the same period.

More than 85% of participants had class II or class III severe obesity at baseline. Researchers used CDC age-specific and sex-specific BMI growth charts to classify the children. Semaglutide moved many treated participants into normal-weight or overweight categories.

Trial Covers 165 Children Across Multiple Countries

STEP Young enrolled 165 children in a randomized, double-blind, placebo-controlled multinational phase 3 trial. Participants received semaglutide or placebo alongside diet changes and increased physical activity. Novo Nordisk used weight-based dosing, with maximum semaglutide doses of 1.7 mg or 2.4 mg.

The primary endpoint measured the percentage change in BMI from baseline through week 68. A secondary endpoint assessed whether children improved their BMI classification during treatment. Other endpoints covered cardiovascular risk factors, glucose metabolism, body measurements, and body composition.

Novo Nordisk designed STEP Young to meet post-marketing requirements for its semaglutide development program. The program follows earlier phase 3 studies involving adults and adolescents with obesity. Novo Nordisk will present detailed results at ObesityWeek 2026 in Washington from November 14 through November 17.

Safety Findings Match Earlier Semaglutide Studies

Novo Nordisk reported no new safety concerns during the STEP Young trial. The company said safety and tolerability matched earlier semaglutide and liraglutide studies. Researchers also identified no safety concerns involving growth or pubertal development.

Childhood obesity carries immediate and long-term risks for physical and mental health. The condition can increase cardiovascular risks and often continues into adulthood without effective treatment. Global estimates counted 177 million children aged five to 19 living with obesity in 2025.

That figure could reach 228 million by 2040, increasing demand for effective pediatric obesity treatments. Semaglutide could expand treatment options when lifestyle changes alone do not produce sufficient results. The STEP Young data strengthens Novo Nordisk’s pediatric obesity program as NVO shares remain under pressure.

✨ Limited Time Offer